slimvictor
Bluelight Crew
Identification of suspect substances depends on reference materials that are in short supply
By Daniel Cressey and Nature magazine | August 31, 2011
Attempts to understand and control new synthetic recreational drugs are being hindered by analysis laboratories' inability to obtain pure samples of the compounds, experts say.
The growing problem of synthetic drugs — which include mimics of cannabis and amphetamine — came to the fore in the United Kingdom last year as politicians rushed to ban mephedrone, which had been linked in the media to several deaths. Mephedrone and several related compounds, known collectively as cathinones, are now controlled substances in the United Kingdom and in many other countries. But new drugs are already appearing that circumvent these bans.
In order to determine what a substance actually is, analytical chemists need to compare it with a pure version of what they think it might be, using techniques such as gas-column mass spectrometry (GCMS). But Robert Lantz and Oliver Sutcliffe told reporters at the American Chemical Society meeting in Denver, Colorado, that these 'reference standards' are hard to come by for emerging synthetic drugs.
cont at
http://www.scientificamerican.com/article.cfm?id=shortage-of-pure-drug-samples
By Daniel Cressey and Nature magazine | August 31, 2011
Attempts to understand and control new synthetic recreational drugs are being hindered by analysis laboratories' inability to obtain pure samples of the compounds, experts say.
The growing problem of synthetic drugs — which include mimics of cannabis and amphetamine — came to the fore in the United Kingdom last year as politicians rushed to ban mephedrone, which had been linked in the media to several deaths. Mephedrone and several related compounds, known collectively as cathinones, are now controlled substances in the United Kingdom and in many other countries. But new drugs are already appearing that circumvent these bans.
In order to determine what a substance actually is, analytical chemists need to compare it with a pure version of what they think it might be, using techniques such as gas-column mass spectrometry (GCMS). But Robert Lantz and Oliver Sutcliffe told reporters at the American Chemical Society meeting in Denver, Colorado, that these 'reference standards' are hard to come by for emerging synthetic drugs.
cont at
http://www.scientificamerican.com/article.cfm?id=shortage-of-pure-drug-samples
